Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

• Status: Terminated
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Metastatic colorectal carcinoma

• Suitable for first-line treatment of metastatic disease

Exclusion Criteria:

• Peripheral neuropathy greater than Grade 1

• Adjuvant therapy within 6 months prior to study treatment

• Prior oxaliplatin

• Prior pelvic or whole abdomen radiation

• Any history of coronary angioplasty or history of myocardial infarction